Cytosorbents (CTSO) Shares Outstanding (Weighted Average) (2010 - 2026)

Cytosorbents has reported Shares Outstanding (Weighted Average) for 17 years, with the latest figure at $62.7 million in Q1 2026.

• For the quarter ending Q1 2026, Shares Outstanding (Weighted Average) rose 3.3% year-over-year to $62.7 million; the trailing twelve-month figure through Mar 2026 stood at $62.7 million (up 3.3% YoY), and the FY2025 full-year result was $62.2 million, up 14.32% from the prior year.
• Shares Outstanding (Weighted Average) for Q1 2026 stood at $62.7 million, up from $62.2 million in the prior quarter.
• The five-year high for Shares Outstanding (Weighted Average) was $62.7 million in Q1 2026, with the low at $2.7 million in Q4 2023.
• Historically, Shares Outstanding (Weighted Average) has averaged $49.2 million across 5 years, with a median of $54.3 million in 2024.
• Annual changes were most pronounced in 2023 — Shares Outstanding (Weighted Average) slumped 93.79% — and 2024, when it soared 1911.21%.
• Cytosorbents' Shares Outstanding (Weighted Average) stood at $43.6 million in 2022, then tumbled by 93.79% to $2.7 million in 2023, then soared by 1911.21% to $54.4 million in 2024, then increased by 14.32% to $62.2 million in 2025, then grew by 0.81% to $62.7 million in 2026.
• The last three Shares Outstanding (Weighted Average) figures came in at $62.7 million (Q1 2026), $62.2 million (Q4 2025), and $62.0 million (Q3 2025), per Business Quant data.